Biosimilar safety considerations in clinical practice

Seminars in Oncology

Volumn 41, Issue SUPPL. 1, 2014, Pages

  Choy, Edwin ^a   Allen Jacobs, Ira ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENTS; BIOSIMILAR PHARMACEUTICALS; DRUG APPROVAL; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; PHARMACOVIGILANCE; PRACTICE GUIDELINES AS TOPIC; SAFETY; THERAPEUTIC EQUIVALENCY;

EID: 84894590924     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.12.001     Document Type: Article

References (48)

1. A.D. Zelenetz, I. Ahmed, E.L. Braud, J.D. Cross, N. Davenport-Ennis, and B.D. Dickinson et al. Safety perspectives NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives J Natl Compr Canc Netw 9 2011 S-1 22
2. Generics and Biosimilars Initiative Online. US$67 billion worth of biosimilar patents expiring before 2020. http://www.gabionline.net/Biosimilars/ General/US-67-billion-worth-of-biosimilar-patents-expiring-before-2020. Accessed September 20, 2013.
3. US Food and Drug Administration. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM291128.pdf. Accessed September 5, 2013.
4. M. Weise, M.-C. Bielsky, and K. de Smet et al. Biosimilars: what clinicians should know Blood 120 2012 5111 5117
5. US Food and Drug Administration. Guidance for industry: biosimilars: questions and answers regarding implementation of the biologics price competition and innovation act of 2009. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM273001.pdf Accessed September 20, 2013.
6. US Food and Drug Administration. Guidance for industry: quality considerations in demonstrating biosimilarity to a reference protein product. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM291134.pdf Accessed September 20, 2013.
7. H. Mellstedt, D. Niederwieser, and H. Ludwig The challenge of biosimilars Ann Oncol 19 2008 411 419
8. M. Weise, M.-C. Bielsky, and K. De Smet et al. Biosimilars-why terminology matters Nat Biotechnol 29 2011 690 693
9. N. Casadevall, I.R. Edwards, and T. Felix et al. Pharmacovigilance and biosimilars: considerations, needs and challenges Expert Opin Biol Ther 13 2013 1039 1047
10. J. Wang, and S.-C. Chow On the regulatory approval pathway of biosimilar products Pharmaceuticals 5 2012 353 368
11. European Medicines Agency. Committee for Medicinal Products for Human Use(CHMP). Guideline on similar biological medicinal products. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500003517.pdf. Accessed September 16, 2013.
12. European Medicines Agency. Omnitrope. http://www.ema.europa.eu/ema/index. jsp?curl=pages/medicines/human/medicines/000607/human-med-000946.jsp&mid= WC0b01ac058001d124. Accessed September 5, 2013.
13. US Food and Drug Administration. Biosimilarity. http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm290967.htm. Accessed September 5, 2013.
14. W. Jeske, J.M. Walenga, D. Hoppensteadt, and J. Fareed Update on the safety and bioequivalence of biosimilars-focus on enoxaparin Drug Healthc Patient Saf 5 2013 133 141
15. Generics and Biosimilars Initiative Online. Biosimilar monoclonal antibodies - challenges and opportunities in Europe. http://gabi-journal.net/ biosimilar-monoclonal-antibodies-challenges-and-opportunities-in-europe.html. Accessed September 12, 2013.
16. European Medicines Agency. Guideline on immunogenicity of biotechnology-derived therapeutic proteins. http://www.ema.europa.eu/docs/en-GB/ document-library/Scientific-guideline/2009/09/WC500003947.pdf. Accessed September 5, 2013.
17. P.J. Declerck Biosimilar monoclonal antibodies: a science-based regulatory challenge Expert Opin Biol Ther 13 2013 153 156
18. J. Kay, and J.S. Smolen Biosimilars to treat inflammatory arthritis: the challenge of proving identity Ann Rheum Dis 72 2013 1589 1593
19. Jack A. Regulators pave the way for 'biosimilar' drugs. Financial Times. June 28, 2013.
20. Decision Resources. Biosimilar ESAs to account for 40 percent of the G7 ESA market in 2020. October 27, 2011.
21. European Medicines Agency. Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. http://www.ema.europa. eu/docs/en-GB/document-library/Scientific-guideline/2012/06/WC500128688.pdf. Accessed September 5, 2013.
22. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Summary of opinion (initial authorization) Inflectra. http://www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion-Initial- authorisation/human/002778/WC500144831.pdf. Accessed September 23, 2013.
23. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Summary of opinion (initial authorization) Remsima. http://www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion-Initial- authorisation/human/002576/WC500144832.pdf. Accessed September 23, 2013.
24. Hospira's Inflectra (infliximab) the first biosimilar monoclonal antibody to be approved in Europe. [press release]. Leamington Spa, England/PRNewswire/ - Hospira; September 10, 2013.
25. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Inflectra Summary of Product Characteristics. http://www.ema.europa.eu. Accessed September 23, 2013.
26. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Remsima Summary of Product Characteristics. http://www.ema.europa.edu. Accessed September 23, 2013.
27. D.H. Yoo, P. Hrycaj, P. Miranda, E. Ramiterre, M. Piotrowski, and S. Shevchuk et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study Ann Rheum Dis 72 2013 1613 1620
28. S. Kozlowski, J. Woodcock, K. Midthun, and R.B. Sherman Developing the nation's biosimilars program N Engl J Med 365 2011 385 388
29. A. Beck, and J.M. Reichert Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry MAbs 5 5 2013 [Epub ahead of print]
30. J.F. Lee, J.B. Litten, and G. Grampp Comparability and biosimilarity: considerations for the healthcare provider Curr Med Res Opin 28 2012 1053 1058
31. M. Nowicki Basic facts about biosimilars Kidney Blood Press Res 30 2007 267 272
32. M. Kuhlmann, and A. Covic The protein science of biosimilars Nephrol Dial Transplant 21 Suppl 5 2006 v4 v8
33. World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs). http://www.who.int/biologicals/areas/biological- therapeutics/BIOTHERAPEUTICS-FOR-WEB-22APRIL2010.pdf. Accessed September 5, 2013.
34. H. Schellekens, and J.-C. Ryff 'Biogenerics': the off-patent biotech products. 2002 Trends Pharm Sci 23 2002 119 121
35. J. Woodcock, J. Griffin, and R. Behrman et al. The FDA's assessment of follow-on protein products: a historical perspective Nat Rev Drug Discov 6 2007 437 442
36. K. Boven, S. Stryker, and J. Knight et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes Kidney Int 67 2005 2346 2353
37. J. Kanter, and R. Feldman Understanding and incentivizing biosimilars The Hastings Law Journal 64 2012 57 83
38. X.Y. Cai, J. Thomas, C. Cullen, and D. Gouty Challenges of developing and validating immunogenicity assays to support comparability studies for biosimilar drug development Bioanalysis 4 2012 2169 2177
39. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2009/09/WC500003947.pdf. Accessed September 16, 2013.
40. H. Schellekens Bioequivalence and the immunogenicity of biopharmaceuticals Nat Rev Drug Discov 1 2002 457 462
41. US Food and Drug Administration. Guidance for industry: good pharmacovigilance practices and pharmacoepidemiologic assessment. US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Rockville, MD; 2005.
42. H.C. Ebbers, S.A. Crow, A.G. Vulto, and H. Schellekens Interchangeability, immunogenicity and biosimilars Nat Biotechnol 30 2012 1186 1190
43. Calvo B, Zuniga L. Risk management plan and pharmacovigilance system - biopharmaceuticals: biosimilars risk management trends. In: Nota G, ed. Risk management trends. InTech; 2011:chapter 13. http://www.intechopen.com/books/ risk-management-trends/risk-management-plan-and-pharmacovigilance-system- biopharmaceuticals-biosimilars. Accessed September 23, 2013.
44. US Food and Drug Administration. Approved risk evaluation and mitigation strategies. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm. Accessed September 23, 2013.
45. US Food and Drug Administration. Guidance for Industry Safety Labeling Changes - Implementation of Section 505 (o) (4) of the FD&C Act http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM250783.pdf Accessed September 23, 2013.
46. Rader RA. Nomenclature of new biosimilars will be highly controversial. http://www.bioprocessintl.com/multimedia/archive/00173/BPI-A-110906AR04-O- 173322a.pdf. Accessed September 5, 2013.
47. World Health Organization. WHO informal consultation on International Nonproprietary Names (INN) Policy for biosimilar products. http://www.who.int/ medicines/services/inn/BiosimilarsINN-Report.pdf. Accessed September 5, 2013.
48. Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards to pharmacovigilance, directive 2001/83/EC on the Community code relating to medicinal products for human use. Off J Eur Union. 2010;348:74-99.